Next-generation sequencing, should I use anti-HER2 therapy for HER2 -amplified tumors off-label? Illustrating an extrapolation framework.
Doah ChoSarah Sally J LordJohn SimesWendy CooperMichael FriedlanderSusie BaeChee Khoon LeePublished in: Therapeutic advances in medical oncology (2022)
We present a systematic approach for appraising evidence to support extrapolating trastuzumab benefits from established indications to off-label applications. Extrapolation criteria and areas of uncertainty to inform SDM are outlined. This framework is potentially generalizable to other tumor-agnostic biomarker-targeted therapy scenarios. It is a practical approach for clinicians to apply in routine practice and should be considered by molecular tumor boards who make off-label recommendations.